MedTrace Logo

Role of Huachansu in Treating Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPase

NCT01715532 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2015-12-18

No results posted yet for this study

Summary

Primary Outcome Measures:

\- To compare the progression free survival(PFS) in patients with unresectable hepatocellular carcinoma(HCC) treated with transcatheter arterial chemoembolization(TACE) with or without Huachansu, and the correlation between PFS and expression of peripheral Na+/K+-ATPase α3 family.

Secondary Outcome Measures:

\- To compare the overall survival(OS), objective response rate(ORR), and side effects of treating HCC with TACE plus Huachansu or TACE alone.

Exploratory Outcome Measures:

\- To evaluate the correlation between prognosis and expression of peripheral Na+/K+-ATPase α3 family.

Conditions

  • Carcinoma, Hepatocellular

Interventions

DRUG

Huachansu

OTHER

TACE

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Hao Chen, MD, Ph D · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01715532 on ClinicalTrials.gov